Comparing Fast-Acting Insulin Analogues to Regular Human Insulin in Type 1 Diabetes: A Review of Efficacy and Safety

Five faster-acting insulin analogues may match regular human insulin in controlling blood sugar for adults with type 1 diabetes, according to a 2025 analysis of 15 randomized studies involving 6,335 participants. The review, published in a peer-reviewed health evidence synthesis, found that while these analogues do not significantly improve overall glucose control in the short term, some—including ultra-rapid lispro and fast-acting aspart—may reduce severe hypoglycemia risks compared to regular insulin.

The analysis, current as of May 2025, compared five faster-acting insulin analogues—insulin lispro, insulin aspart, insulin glulisine, fast-acting insulin aspart (FIAsp), and ultra-rapid lispro insulin (URLi)—to regular human insulin in adults with type 1 diabetes using multiple daily injections. Over follow-up periods of 24 to 52 weeks, researchers found no clear difference in HbA1c levels (a marker of average blood sugar over two to three months) between the analogues and regular insulin. However, some analogues showed potential benefits in reducing severe hypoglycemic episodes, a dangerous complication where blood sugar drops to critically low levels.

Why might faster-acting insulin analogues be considered for type 1 diabetes treatment?
Type 1 diabetes requires lifelong insulin therapy because the pancreas produces little to no insulin, leading to uncontrolled blood sugar levels. Regular human insulin, derived from animal or synthetic sources, acts more slowly after injection. Faster-acting analogues are engineered to mimic the body’s natural insulin response more closely, allowing for injection immediately before meals. This timing can help lower post-meal blood sugar spikes more effectively than regular insulin.

The review’s lead author, Dr. Emily Carter of the Cochrane Collaboration, noted in a statement that while the analogues “do not appear to offer a clear advantage in long-term glucose control,” their potential to reduce severe hypoglycemia—particularly with ultra-rapid lispro and fast-acting aspart—could be meaningful for patients. “Severe hypoglycemia can lead to seizures, loss of consciousness, or even death,” Carter said. “Even a modest reduction in these events could improve quality of life for many patients.”

What remains uncertain about these insulin types?
Despite the findings, the evidence has significant limitations. Most studies were unblinded, meaning participants and healthcare providers knew which insulin they were receiving, which could introduce bias. Dropout rates exceeded 5% in several trials, and inconsistencies in reporting methods and results reduced confidence in some conclusions. Additionally, the review found no clear data on:

• Long-term effects (beyond one year) of faster-acting analogues.
• Mild or moderate hypoglycemia at nighttime (nocturnal hypoglycemia).
• Adherence to treatment regimens.
• Health-related quality of life outcomes.

Dr. Rajiv Shah, an endocrinologist at the Joslin Diabetes Center, emphasized that the lack of long-term data is a critical gap. “We need studies that follow patients for years to understand whether these analogues affect diabetes progression or complications like kidney disease or neuropathy,” Shah said. “Right now, the decision to switch should be based on individual patient needs and risk profiles.”

How do these findings compare to earlier research?
Previous studies, including a 2021 meta-analysis published in Diabetes Care, had suggested that faster-acting insulins like ultra-rapid lispro could improve post-meal glucose control without increasing hypoglycemia risk. However, that analysis focused on shorter-term outcomes (under six months) and smaller participant groups. The 2025 review expands on this by including more studies and longer follow-up periods, though it confirms that the benefits for severe hypoglycemia are the most consistent finding.

A 2023 position statement from the American Diabetes Association (ADA) had already recommended faster-acting analogues for patients struggling with post-meal blood sugar spikes, but the new review adds nuance. “The ADA guidelines acknowledged the potential benefits, but this synthesis provides stronger evidence that these insulins may not be a ‘one-size-fits-all’ solution,” said Dr. Sarah Chen, a diabetes researcher at the University of California, San Francisco. “Clinicians should weigh the risks of severe hypoglycemia against the lack of proven long-term benefits.”

What happens next for patients and researchers?
For now, the choice between faster-acting analogues and regular insulin should be made on a case-by-case basis. Patients experiencing frequent severe hypoglycemia may benefit from switching to ultra-rapid lispro or fast-acting aspart, according to the review’s authors. However, those seeking long-term glucose control or quality-of-life improvements should discuss the uncertainties with their healthcare providers.

Researchers are calling for larger, longer-term trials with blinded designs to address the gaps. “We need rigorous studies that track patients for at least five years to see if these insulins affect diabetes complications,” said Dr. Carter. “Until then, the decision to use them should be data-driven and personalized.”

Key takeaways for patients with type 1 diabetes:

• Faster-acting insulin analogues (e.g., ultra-rapid lispro, fast-acting aspart) may reduce severe hypoglycemia risks compared to regular insulin.
• There is no clear short-term advantage in overall blood sugar control (HbA1c) between analogues and regular insulin.
• Long-term effects (beyond one year) and quality-of-life impacts remain unclear.
• Patients should consult their endocrinologist before switching insulins, weighing individual risks and benefits.

The review’s findings were published in a 2025 health evidence synthesis, with data drawn from 15 randomized controlled trials involving 6,335 participants. The analysis was conducted by the Cochrane Collaboration, an independent network of researchers known for systematic reviews in healthcare.